Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing

NeuroMolecular Medicine

Volumn 16, Issue 4, 2014, Pages 686-696

  Bachmeier, Corbin ^a,b   Shackleton, Ben ^a,b   Ojo, Joseph ^a   Paris, Daniel ^a,b   Mullan, Michael ^a   Crawford, Fiona ^a,b  

^a ROSKAMP INSTITUTE   (United States)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

Apolipoprotein E; Beta amyloid; Blood brain barrier; Lipoprotein receptor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; APOLIPOPROTEIN E4; ISOPROTEIN; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP1 PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ANIMAL; BLOOD BRAIN BARRIER; BRAIN; C57BL MOUSE; CAUDATE NUCLEUS; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; HUMAN; INJECTION; KNOCKOUT MOUSE; MALE; METABOLISM; MICROVASCULATURE; MOUSE; PHYSIOLOGY; SOLUBILITY; TRANSGENIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CAUDATE NUCLEUS; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; INJECTIONS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROVESSELS; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; RECEPTORS, LDL; SOLUBILITY;

EID: 84923319414     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-014-8318-6     Document Type: Article

References (70)

1. Akram, A., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. (2012). Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiology of Aging,33(3), e1–e14.
2. Arelin, K., Kinoshita, A., Whelan, C. M., Irizarry, M. C., Rebeck, G. W., Strickland, D. K., et al. (2002). LRP and senile plaques in Alzheimer’s disease: Colocalization with apolipoprotein E and with activated astrocytes. Molecular Brain Research,104(1), 38–46.
3. Armstrong, R. A. (2009). The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathologica,47(4), 289–299.
4. Bachmeier, C., Mullan, M., & Paris, D. (2010). Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood–brain barrier. Cytotechnology,62(6), 519–529.
5. Bachmeier, C., Paris, D., Beaulieu-Abdelahad, D., Mouzon, B., Mullan, M., & Crawford, F. (2013). A multifaceted role for apoE in the clearance of beta-amyloid across the blood–brain barrier. Neurodegenerative Diseases,11(1), 13–21.
6. Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., et al. (2009). Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. Journal of Neuroscience,29(21), 6771–6779.
7. Basak, J. M., Verghese, P. B., Yoon, H., Kim, J., & Holtzman, D. M. (2012). Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. Journal of Biological Chemistry,287(17), 13959–13971.
8. Begg, M. J., Sturrock, E. D., & van der Westhuyzen, D. R. (2004). Soluble LDL-R are formed by cell surface cleavage in response to phorbol esters. European Journal of Biochemistry,271(3), 524–533.
9. Bekris, L. M., Millard, S. P., Galloway, N. M., Vuletic, S., Albers, J. J., Li, G., et al. (2008). Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. Journal of Alzheimer’s Disease,13(3), 255–266.
10. Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., et al. (2007). Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. Journal of Cerebral Blood Flow and Metabolism,27(5), 909–918.
11. Boche, D., Nicoll, J. A., & Weller, R. O. (2005). Immunotherapy for Alzheimer’s disease and other dementias. Current Opinion in Neurology,18(6), 720–725.
12. Bogdanovic, N., Corder, E., Lannfelt, L., & Winblad, B. (2002). APOE polymorphism and clinical duration determine regional neuropathology in Swedish APP(670, 671) mutation carriers: Implications for late-onset Alzheimer’s disease. Journal of Cellular and Molecular Medicine,6(2), 199–214.
13. Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer’s disease: Pathways, pathogenesis and therapy. Nature Reviews Neuroscience,10(5), 333–344.
14. Bu, G., Maksymovitch, E. A., Nerbonne, J. M., & Schwartz, A. L. (1994). Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. Journal of Biological Chemistry,269(28), 18521–18528.
15. Buttini, M., Orth, M., Bellosta, S., Akeefe, H., Pitas, R. E., Wyss-Coray, T., et al. (1999). Expression of human apolipoprotein E3 or E4 in the brains of Apoe−/− mice: Isoform-specific effects on neurodegeneration. Journal of Neuroscience,19(12), 4867–4880.
16. Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., et al. (2012). Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. Proc Natl Acad Sci USA,109(38), 15502–15507.
17. Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., et al. (2011). Human apoE isoforms differentially regulate brain amyloid–beta peptide clearance. Science Translational Medicine,3(89), 57–67.
18. Citron, M. (2010). Alzheimer’s disease: Strategies for disease modification. Nature Reviews Drug Discovery,9(5), 387–398.
19. Coisne, C., Dehouck, L., Faveeuw, C., Delplace, Y., Miller, F., Landry, C., et al. (2005). Mouse syngenic in vitro blood–brain barrier model: A new tool to examine inflammatory events in cerebral endothelium. Laboratory Investigation,85(6), 734–746.
20. Deane, R., Bell, R. D., Sagare, A., & Zlokovic, B. V. (2009). Clearance of amyloid–beta peptide across the blood–brain barrier: Implication for therapies in Alzheimer’s disease. CNS and Neurological Disorders: Drug Targets,8(1), 16–30.
21. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., et al. (2008). apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. The Journal of Clinical Investigation,118(12), 4002–4013.
22. DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O’Dell, M. A., Taylor, J. W., et al. (2004). ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron,41(2), 193–202.
23. Dodart, J. C., Bales, K. R., Johnstone, E. M., Little, S. P., & Paul, S. M. (2002). Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice. Brain Research,955(1–2), 191–199.
24. Erickson, M. A., Hartvigson, P. E., Morofuji, Y., Owen, J. B., Butterfield, D. A., & Banks, W. A. (2012). Lipopolysaccharide impairs amyloid beta efflux from brain: Altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood–brain barrier. Journal of Neuroinflammation,9, 150–164.
25. Etique, N., Verzeaux, L., Dedieu, S., & Emonard, H. (2013). LRP-1: A checkpoint for the extracellular matrix proteolysis. BioMed Research International,2013, 1–7.
26. Fan, J., Stukas, S., Wong, C., Chan, J., May, S., DeValle, N., et al. (2011). An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia. Journal of Lipid Research,52(9), 1605–1616.
27. Fryer, J. D., Taylor, J. W., DeMattos, R. B., Bales, K. R., Paul, S. M., Parsadanian, M., et al. (2003). Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. Journal of Neuroscience,23(21), 7889–7896.
28. Gilbert, B. J. (2013). The role of amyloid beta in the pathogenesis of Alzheimer’s disease. Journal of Clinical Pathology,66(5), 362–366.
29. Gorovoy, M., Gaultier, A., Campana, W. M., Firestein, G. S., & Gonias, S. L. (2010). Inflammatory mediators promote production of shed LRP1/CD91, which regulates cell signaling and cytokine expression by macrophages. Journal of Leukocyte Biology,88(4), 769–778.
30. Grimsley, P. G., Quinn, K. A., & Owensby, D. A. (1998). Soluble low-density lipoprotein receptor-related protein. Trends in Cardiovascular Medicine,8(8), 363–368.
31. Hayashi, H., Campenot, R. B., Vance, D. E., & Vance, J. E. (2007). Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. Journal of Neuroscience,27(8), 1933–1941.
32. Hoe, H. S., & Rebeck, G. W. (2005). Regulation of ApoE receptor proteolysis by ligand binding. Molecular Brain Research,137(1–2), 31–39.
33. Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., et al. (2000). Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA,97(6), 2892–2897.
34. Kajiwara, Y., Franciosi, S., Takahashi, N., Krug, L., Schmeidler, J., Taddei, K., et al. (2010). Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer’s disease. Molecular Neurodegeneration,5(1), 1–11.
35. Kanekiyo, T., Cirrito, J. R., Liu, C. C., Shinohara, M., Li, J., Schuler, D. R., et al. (2013). Neuronal clearance of amyloid-beta by endocytic receptor LRP1. Journal of Neuroscience,33(49), 19276–19283.
36. Kanekiyo, T., Liu, C. C., Shinohara, M., Li, J., & Bu, G. (2012). LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer’s amyloid-beta. Journal of Neuroscience,32(46), 16458–16465.
37. Kennelly, S., Abdullah, L., Kenny, R. A., Mathura, V., Luis, C. A., Mouzon, B., et al. (2012). Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients—An open-label trial. International Journal of Geriatric Psychiatry,27(4), 415–422.
38. Kim, J., Basak, J. M., & Holtzman, D. M. (2009). The role of apolipoprotein E in Alzheimer’s disease. Neuron,63(3), 287–303.
39. Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., et al. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nature Medicine,10(7), 719–726.
40. Lee, C. Y., & Landreth, G. E. (2010). The role of microglia in amyloid clearance from the AD brain. Journal of Neural Transmission,117(8), 949–960.
41. Liu, Q., Zhang, J., Tran, H., Verbeek, M. M., Reiss, K., Estus, S., et al. (2009). LRP1 shedding in human brain: Roles of ADAM10 and ADAM17. Molecular Neurodegeneration,4, 17–23.
42. Manelli, A. M., Bulfinch, L. C., Sullivan, P. M., & LaDu, M. J. (2007). Abeta42 neurotoxicity in primary co-cultures: Effect of apoE isoform and Abeta conformation. Neurobiology of Aging,28(8), 1139–1147.
43. Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., et al. (1997). Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood–brain barrier transport of circulating Alzheimer’s amyloid beta. Journal of Neurochemistry,69(5), 1995–2004.
44. Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., et al. (2010). Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science,330(6012), 1774.
45. Mitchell, R. W., On, N. H., Del Bigio, M. R., Miller, D. W., & Hatch, G. M. (2011). Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. Journal of Neurochemistry,117(4), 735–746.
46. Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C. H., Laporte, V., et al. (2011). Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood–brain barrier. Molecular Medicine,17(3–4), 149–162.
47. Piedrahita, J. A., Zhang, S. H., Hagaman, J. R., Oliver, P. M., & Maeda, N. (1992). Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA,89(10), 4471–4475.
48. Qiu, Z., Strickland, D. K., Hyman, B. T., & Rebeck, G. W. (2001). Elevation of LDL receptor-related protein levels via ligand interactions in Alzheimer disease and in vitro. Journal of Neuropathology and Experimental Neurology,60(5), 430–440.
49. Quinn, K. A., Grimsley, P. G., Dai, Y. P., Tapner, M., Chesterman, C. N., & Owensby, D. A. (1997). Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. Journal of Biological Chemistry,272(38), 23946–23951.
50. Rebeck, G. W., LaDu, M. J., Estus, S., Bu, G., & Weeber, E. J. (2006). The generation and function of soluble apoE receptors in the CNS. Molecular Neurodegeneration,1, 15–27.
51. Reitz, C. (2012). Alzheimer’s disease and the amyloid cascade hypothesis: A critical review. International Journal of Alzheimers Disease,2012, 1–11.
52. Risner, M. E., Saunders, A. M., Altman, J. F., Ormandy, G. C., Craft, S., Foley, I. M., et al. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics Journal,6(4), 246–254.
53. Ruzali, W. A., Kehoe, P. G., & Love, S. (2012). LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: Relationship to cerebral amyloid angiopathy and APOE status. Neuroscience Letters,525(2), 123–128.
54. Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology,73(24), 2061–2070.
55. Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., et al. (1993). Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA,90(20), 9649–9653.
56. Selvais, C., Dedieu, S., Hornebeck, W., & Emonard, H. (2010). Post-translational proteolytic events influence LRP-1 functions. BioMedical Materials and Engineering,20(3), 203–207.
57. Sen, A., Alkon, D. L., & Nelson, T. J. (2012). Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon. Journal of Biological Chemistry,287(19), 15947–15958.
58. Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine,1(1), 1–23.
59. Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., et al. (2000). Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. The Journal of Clinical Investigation,106(12), 1489–1499.
60. Shinohara, M., Petersen, R. C., Dickson, D. W., & Bu, G. (2013). Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: Potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathologica,125(4), 535–547.
61. Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., et al. (1997). Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. Journal of Biological Chemistry,272(29), 17972–17980.
62. Triguero, D., Buciak, J., & Pardridge, W. M. (1990). Capillary depletion method for quantification of blood–brain barrier transport of circulating peptides and plasma proteins. Journal of Neurochemistry,54(6), 1882–1888.
63. Ulrich, J. D., Burchett, J. M., Restivo, J. L., Schuler, D. R., Verghese, P. B., Mahan, T. E., et al. (2013). In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Molecular Neurodegeneration,8(13), 1–7.
64. Verghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., et al. (2013). ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci USA,110(19), E1807–E1816.
65. Wahrle, S. E., Shah, A. R., Fagan, A. M., Smemo, S., Kauwe, J. S., Grupe, A., et al. (2007). Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Molecular Neurodegeneration,2, 1–9.
66. Wilhelmus, M. M., Otte-Holler, I., van Triel, J. J., Veerhuis, R., Maat-Schieman, M. L., Bu, G., et al. (2007). Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. American Journal of Pathology,171(6), 1989–1999.
67. Wygrecka, M., Wilhelm, J., Jablonska, E., Zakrzewicz, D., Preissner, K. T., Seeger, W., et al. (2011). Shedding of low-density lipoprotein receptor-related protein-1 in acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine,184(4), 438–448.
68. Yamauchi, K., Tozuka, M., Nakabayashi, T., Sugano, M., Hidaka, H., Kondo, Y., et al. (1999). Apolipoprotein E in cerebrospinal fluid: Relation to phenotype and plasma apolipoprotein E concentrations. Clinical Chemistry,45(4), 497–504.
69. Zaiou, M., Arnold, K. S., Newhouse, Y. M., Innerarity, T. L., Weisgraber, K. H., Segall, M. L., et al. (2000). Apolipoprotein E–low density lipoprotein receptor interaction. Influences of basic residue and amphipathic α–helix organization in the ligand. Journal of Lipid Research,41(7), 1087–1095.
70. Zhong, N., & Weisgraber, K. H. (2009). Understanding the basis for the association of apoE4 with Alzheimer’s disease: Opening the door for therapeutic approaches. Current Alzheimer Research,6(5), 415–418.